Participant flow

Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma · Source last updated 2022-03-02

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Patients receive trametinib orally PO QD (once daily) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with progressive disease or who achieve less than PR after 4 courses may also receive Akt inhibitor GSK2141795 PO daily on days 1-28. Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies Trametinib: Given PO Uprosertib: Given PO

   id

   FG000

   title

   Treatment (Trametinib, Akt Inhibitor GSK2141795)

periods

1. milestones

   1. achievements

      1. comment

         Includes pts receiving Single agent Trametinib and pts who are receiving Trametinib with AKT Inhibitor GSK2141795

         group Id

         FG000

         num Subjects

         25

      type

      STARTED

   2. achievements

      1. comment

         Patients with progressive disease or who achieve less than PR after 4 courses also received Akt inhibitor GSK2141795 PO daily on days 1-28 along with Tremetinib

         group Id

         FG000

         num Subjects

         12

      type

      Dual Therapy With Trametinib and GSK2141795

   3. achievements

      1. comment

         Note: 25 patients enrolled, however, one patient unevaluable was not included in analysis

         group Id

         FG000

         num Subjects

         25

      type

      COMPLETED

   4. achievements

      1. group Id

         FG000

         num Subjects

         0

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice